American Well Corp (AMWL) Form 8-K — Nov 3, 2026
Amwell reported Q3 2026 revenue of $49.0 million, exceeding its previously provided guidance range, with subscription revenue of $23.9 million and Amwell Medical Group visit revenue of $23.7 million. The company raised its full-year 2026 revenue outlook to $204-$206 million (from $200-$205 million) and improved its adjusted EBITDA outlook to ($8) million-($7) million, while guiding Q4 revenue to $48-$50 million and Q4 adjusted EBITDA to $0-$1 million. However, revenue declined about 13% year-over-year from $56.3 million, the net loss widened to ($11.0) million from ($9.6) million in Q2, and adjusted EBITDA deteriorated to ($3.6) million from ($1.2) million sequentially.
Key figures
- Revenue
- 49000000
- Guidance
- FY2026 revenue raised to $204M-$206M (from $200M-$205M); FY2026 adjusted EBITDA raised to ($8)M-($7)M; Q4 2026 revenue $48M-$50M, Q4 adjusted EBITDA $0M-$1M; AMG visits 1.32M-1.37M; expects positive operating cash flow in Q4 2026
- Revenue Yoy
- -13.0%
- Total Assets
- 309216000
- Cash Position
- 180786000
- Gross margin
- 53%
- Platform visits
- 0.8 million
- Amg visit revenue
- 23700000
- Subscription revenue
- 23900000
- Yoy net loss improvement
- Yes
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.